Gerassimos E Voutsinas
Overview
Explore the profile of Gerassimos E Voutsinas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos D, Christopoulou V, Taning C, Avgeris S, Papadopoulou A, Kletsas D, et al.
Arch Insect Biochem Physiol
. 2025 Jan;
118(1):e70028.
PMID: 39835498
The discovery that infections of viruses are pervasive among insects has considerable potential for future applications, such as new strategies for pest control through the manipulation of virus-host interactions. However,...
2.
Taouktsi E, Kyriakou E, Voulgaraki E, Verganelakis D, Krokou S, Rigas S, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139038
p38 Mitogen-Activated Protein Kinase (MAPK) cascades are central regulators of numerous physiological cellular processes, including stress response signaling. In , mitochondrial dysfunction activates a PMK-3/p38 MAPK signaling pathway (MAPK), but...
3.
Drosos Y, Konstantakou E, Bassogianni A, Nikolakopoulos K, Koumoundourou D, Markaki S, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509392
Bladder cancer (BLCA) is the sixth most common type of cancer and has a dismal prognosis if diagnosed late. To identify treatment options for BLCA, we systematically evaluated data from...
4.
Taouktsi E, Kyriakou E, Smyrniotis S, Borbolis F, Bondi L, Avgeris S, et al.
Cells
. 2022 Apr;
11(8).
PMID: 35456042
Cells engage complex surveillance mechanisms to maintain mitochondrial function and protein homeostasis. LonP1 protease is a key component of mitochondrial quality control and has been implicated in human malignancies and...
5.
Giannopoulou A, Velentzas A, Anagnostopoulos A, Agalou A, Papandreou N, Katarachia S, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33922182
Melanoma is classified among the most notoriously aggressive human cancers. Despite the recent progress, due to its propensity for metastasis and resistance to therapy, novel biomarkers and oncogenic molecular drivers...
6.
Iliou A, Panagiotakis A, Giannopoulou A, Benaki D, Kosmopoulou M, Velentzas A, et al.
Int J Mol Sci
. 2020 Mar;
21(5).
PMID: 32164285
Background: Urothelial bladder cancer (UBC) is one of the cancers with the highest mortality rate and prevalence worldwide; however, the clinical management of the disease remains challenging. Metabolomics has emerged...
7.
Giannopoulou A, Velentzas A, Konstantakou E, Avgeris M, Katarachia S, Papandreou N, et al.
Int J Mol Sci
. 2019 Mar;
20(6).
PMID: 30875794
Urinary bladder cancer is a common malignancy, being characterized by substantial patient mortality and management cost. Its high somatic-mutation frequency and molecular heterogeneity usually renders tumors refractory to the applied...
8.
Delimitsou A, Fostira F, Kalfakakou D, Apostolou P, Konstantopoulou I, Kroupis C, et al.
Hum Mutat
. 2019 Mar;
40(5):631-648.
PMID: 30851065
Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants...
9.
Giannopoulou A, Konstantakou E, Velentzas A, Avgeris S, Avgeris M, Papandreou N, et al.
Int J Mol Sci
. 2019 Feb;
20(4).
PMID: 30795533
Background: Skin cancer represents the most common human malignancy, and it includes BCC, SCC, and melanoma. Since melanoma is one of the most aggressive types of cancer, we have herein...
10.
Saetta A, Lazaris A, Miaouli M, Voutsinas G, Patsouris E, Tseleni-Balafouta S
Pathobiology
. 2018 Oct;
85(5-6):304-310.
PMID: 30278467
Background: Malignant cells exhibit significant resistance to FAS-mediated cell death, through different processes, including FAS mutations, soluble FAS expression, or FAS transcriptional dysregulation by P53, eventually escaping from immune surveillance....